Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Dec. 15 '25)

Image
By G.M.

 


    Clin Infect Dis

  1. BIEBELBERG B, Chen T, McKenna C, Kanjilal S, et al
    Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays.
    Clin Infect Dis. 2025 Dec 11:ciaf687. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  2. BRAUNFELD JB, Traub E, Chiou H, Amoon AT, et al
    Community-Driven, Text Message-Based COVID-19 Surveillance System, Los Angeles County, California, USA, 2020-2024.
    Emerg Infect Dis. 2025;31:2109-2117.
    PubMed         Abstract available


    Int J Infect Dis

  3. LI H, LiuPhD J, Fang Q, Li Z, et al
    Pathogen-specific immunity debt in children after prolonged nonpharmaceutical interventions: a cross-sectional study in China.
    Int J Infect Dis. 2025 Dec 3:108278. doi: 10.1016/j.ijid.2025.108278.
    PubMed         Abstract available

  4. JIANG Z, Shan T, Li Y, Han F, et al
    Persistent Attenuation of Lymphocyte Subsets After Mass SARS-CoV-2 Infection.
    Int J Infect Dis. 2025 Dec 5:108287. doi: 10.1016/j.ijid.2025.108287.
    PubMed         Abstract available

  5. AUGELLO M, Bartolomeo FD, Varisco B, Timelli L, et al
    Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study.
    Int J Infect Dis. 2025 Dec 6:108305. doi: 10.1016/j.ijid.2025.108305.
    PubMed         Abstract available

  6. ORDONEZ-MENA JM, Gu X, Joy M, Fan X, et al
    Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022.
    Int J Infect Dis. 2025 Dec 9:108289. doi: 10.1016/j.ijid.2025.108289.
    PubMed         Abstract available

  7. MANDELBOIM M, Atari N, Gur-Arie L, Sefty H, et al
    Age-related distribution of Influenza B and vaccine match in the 2024-2025 season: A multi-season comparative analysis.
    Int J Infect Dis. 2025 Dec 10:108303. doi: 10.1016/j.ijid.2025.108303.
    PubMed         Abstract available

  8. MAEDA K, Miyakawa K, Tanabe M, Kuninaka H, et al
    Risk assessment of SARS-CoV-2 infection from external surfaces and biological samples of COVID-19 corpses.
    Int J Infect Dis. 2025 Dec 10:108298. doi: 10.1016/j.ijid.2025.108298.
    PubMed         Abstract available

  9. NEL I, Minier M, Milojkovic A, De Swardt H, et al
    Alterations of anti-SARS-CoV-2 immune response in children vary according to the nature of their immunosuppression.
    Int J Infect Dis. 2025 Dec 11:108301. doi: 10.1016/j.ijid.2025.108301.
    PubMed         Abstract available


    J Infect

  10. YUE M, Lee S, Tao S, Tomazetto G, et al
    Upper airway transcriptomics early after SARS-CoV-2 infection to identify individuals likely to develop symptomatic infection.
    J Infect. 2025;92:106664.
    PubMed         Abstract available


    J Med Virol

  11. HUANG R, Xu J, Liu Z, Sun T, et al
    Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory.
    J Med Virol. 2025;97:e70740.
    PubMed         Abstract available

  12. MCVOY MA, Kummarapurugu AB
    The Role of ACE2 in SARS-CoV-2 Infection, Pathogenesis, and Antiviral Interventions.
    J Med Virol. 2025;97:e70721.
    PubMed         Abstract available

  13. ZOU Y, Kamoi K, Zong Y, Zhang J, et al
    Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports.
    J Med Virol. 2025;97:e70747.
    PubMed         Abstract available

  14. WINKEL AMAM, de Jonghe BA, Lap CR, Haverkort ME, et al
    Persistent Symptoms in SARS-CoV-2-Infected and Non-Infected Household Members: A Prospective Cohort Study.
    J Med Virol. 2025;97:e70727.
    PubMed         Abstract available

  15. SIMKIN F, Postans M, Pacchiarini N, Song J, et al
    Variance in the Variants: A Comparison of the Symptomatology of SARS-CoV-2 Variants in Wales, February 2020-July 2022.
    J Med Virol. 2025;97:e70717.
    PubMed         Abstract available

  16. TANG X, Xiao Y, Zhong J, Ding T, et al
    Integrative Multi-Omics Analysis Reveals Age-Associated Molecular Mechanisms in SARS-CoV-2 Infection.
    J Med Virol. 2025;97:e70730.
    PubMed         Abstract available


    J Virol

  17. AHMETAJ-SHALA B, Peacock TP, Baillon L, Swann OC, et al
    Resistance of endothelial cells to SARS-CoV-2 infection in vitro.
    J Virol. 2025 Dec 5:e0120525. doi: 10.1128/jvi.01205.
    PubMed         Abstract available


    JAMA

  18. GIAMARELLOS-BOURBOULIS EJ, Kotsaki A, Kotsamidi I, Efthymiou A, et al
    Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
    JAMA. 2025 Dec 8:e2524175. doi: 10.1001/jama.2025.24175.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  19. LIM S, Vagnone PS, Marshall NC, Lees C, et al
    Detection of Paraburkholderia in Clinical Specimens Associated with Use of Nonsterile Ultrasound Gel for Percutaneous Procedures - United States, Canada, and Israel, May 2023?April 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:615-621.
    PubMed         Abstract available

  20. IRVING SA, Rowley EAK, Chickery S, Natarajan K, et al
    Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:607-614.
    PubMed         Abstract available


    Nature

  21. BIEVER C
    The first global pandemic treaty - and the woman who made it happen.
    Nature. 2025;648:520-521.
    PubMed        


    Science

  22. VAN KERKHOVE MD, Ihekweazu C
    Pandemic security needs national leadership.
    Science. 2025;390:1083.
    PubMed         Abstract available

  23. SCOLES S
    AI tools aim to speed up outbreak modeling.
    Science. 2025;390:1089-1090.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »